Photo from wikipedia
Historically, refractory/relapsed (r/r) acute B-lymphoblastic leukemia (ALL) in adults has a dismal prognosis, with less than 10% of patients being long-term survivors, which is only achievable through a bone marrow… Click to show full abstract
Historically, refractory/relapsed (r/r) acute B-lymphoblastic leukemia (ALL) in adults has a dismal prognosis, with less than 10% of patients being long-term survivors, which is only achievable through a bone marrow (BM) transplantation.1 The emergence of targeted therapies for ALL has shown that is possible to reach deep remissions even in these patients, achieving negative minimal residual disease (MRD) status, which is paramount for cure.2 Blinatumomab is a bispecific T-cell engager which binds human CD19 (B lymphoblasts) and CD3 (T-cell), stimulating the formation of a cytolytic synapse and cell lysis.2 Inotuzumab Ozogamicin (IO) is an anti-CD22 monoclonal antibody which delivers a potent cytotoxic agent (calicheamicin) into the cell, inducing apoptosis.3
Journal Title: Hematology, Transfusion and Cell Therapy
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!